We identified six patients with Epstein-Barr virus (EBV)-negative extranodal diffuse large B-cell lymphoma (DLBCL) and immunohistochemical expression of PD-L1 on their tumor cells by examining 283 DLBCL cases with the PD-L1 SP142 clone between 2015 and 2017. They consisted of two men and four women with a median age of 71 years, and were examined in an autopsy (n ¼ 1) and biopsies from the adrenal gland (n ¼ 2), skin (n ¼ 1), pelvic cavity (n ¼ 1), and kidney (n ¼ 1). All showed a monomorphic population of large transformed B-cells leading to diagnoses of DLBCL with two intravascular large B-cell lymphoma (IVLBCL) and one de novo CD5þ type and were featured by an invariable immunephenotype: CD3-, CD20þ, BCL-2þ, and MUM1þ. In addition, CD5 and CD10 were each detected in one case. All cases expressed PD-L1 on >10% to >90% of tumor cells, which was confirmed with two other PD-L1
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease comprising multiple morphologic variants, immunophenotypic and molecular subgroups, and distinct disease entities, which were highlighted in the revised 2017 WHO classification listing. 1 Some of these variants have been pointed out in the current classification because of unique clinical characteristics and a predilection for specific anatomic sites, which often reflects an underlying biological distinctiveness. These include primary DLBCL of the central nervous system (CNS DLBCL); primary testicular DLBCL; primary cutaneous DLBCL, leg type; and intravascular large B-cell lymphoma (IVLBCL), which have a propensity for exclusively affecting the extranodal sites and a higher risk of secondary CNS relapse during their clinical courses. [1] [2] [3] [4] [5] [6] However, the reasons for these peculiar biological behaviors remain unclear.
It is now well known that programmed death-ligand 1 (PD-L1) engages the programmed death 1 (PD-1) receptor on the infiltrating lymphocytes and activates PD-1 signaling, which induces inhibition of PD-L1þ cell activation, resulting in immune evasion. 7 The PD-1/PD-L1 ligand (PD-L1)
pathway inhibitors have revolutionized cancer treatment, producing impressive responses in a broad variety of tumor types. [8] [9] [10] [11] [12] [13] [14] Based on the established breakthrough effect of PD1 blockade, researchers are now investigating PD1 and PD-L1 targeted antibodies for treatment of various lymphomas, especially in relapsed or refractory disease. In parallel, studies have focused on analyzing the PD1/PD-L1 axis for prognostic relevance and prediction of treatment response. With regards to lymphoid malignancies, tumor cell PD-L1 expression is frequently reported in classic Hodgkin lymphoma (CHL), primary mediastinal large B-cell lymphoma (PMBL), and Epstein-Barr virus (EBV)-associated lymphomas, including the EBV-positive DLBCL not otherwise specified (NOS) type and nasal-type extranodal NK/T-cell lymphoma. 10, 11, [14] [15] [16] [17] Moreover, a recent report described a higher incidence of neoplastic PD-L1 overexpression in CNS-DLBCL 18 and testicular DLBCL 19 compared with systemic ordinal cases. These findings suggest that neoplastic PD-L1 expression on tumor cells may play an important role in the pathogenesis of these distinct malignancies that feature exclusive extranodal involvement and high incidences (60 to 70%) of the MYD88 L265P mutation. 20 However, our knowledge of PD-L1þ extranodal DLBCL is still limited because of the small number of cases reported.
In this study, we assessed the immunohistochemical expression of PD-L1 by surveying 528 malignant lymphoma cases, including 283 DLBCLs, with an anti-PD-L1 antibody (SP142 clone) between 2015 and 2017, and identified six cases of extranodal DLBCL with neoplastic PD-L1 expression. Our data suggest that these cases of extranodal DLBCL may constitute a distinct immune evasion-related disease beyond the currently recognized entities of IVLBCL and de novo CD5þ DLBCL.
MATERIALS AND METHODS

Patient samples
For this study, we retrieved data from a consecutive series of 528 lymphoma cases, which were diagnosed as malignant lymphoma in our department between 2015 and 2017, and included consultation cases from collaborating institutions. We excluded the cases with PMBL. All of our patients were immunocompetent. Any cases positive for human immunodeficiency virus type 1 or having a past history of immunodeficiency, e.g., due to organ transplantation, were excluded. Among the anti-PD-L1 antibodies commercially available, the SP142 clone is primarily used for examining the presence or absence of neoplastic PD-L1 expression on tumor cells. One autopsy IVLBCL case, which was reported recently, 21 was included. We collected clinical data and formalin-fixed paraffin-embedded (FFPE) sections from these cases. To confirm the diagnoses and immunophenotypes, all cases were reviewed by three pathologists (Y.S., S.N., and K.K.). Involved sites were examined by biopsy or radiographic evaluation, e.g. computed tomography (CT) or positron emission tomography. The study protocol was approved by the institutional review board of Nagoya University.
Histopathogy and immunophenotypic analysis
We performed immunohistochemical analysis of 4 mm-thick FFPE sections using the following antibodies: BCL-2, BCL-6, CD3, CD5, CD10, CD20 
RESULTS
Patient characteristics
In our series, 283 (54%) of our 528 lymphoma cases were diagnosed as DLBCLs. In the immunohistochemical survey using anti-PD-L1 antibody (SP142 clone), four (50%) of eight EBV-positive DLBCLs of NOS type and six (6%) of 108 extranodal EBV-negative DLBCLs were positive for neoplastic PD-L1 expression on their tumor cells ( Fig. 1 ), testicular DLBCL (n ¼ 5), or primary cutaneous DLBCL, leg type (n ¼ 2) cases expressed neoplastic PD-L1. The CD5 positivity was confirmed in three cases, two of CNS DLBCL and one of DLBCL of the kidney. Table 2 summarizes the clinical features of our six DLBCL patients with neoplastic PD-L1 expression. They were two men and four women with a median age of 71 years (range, 51-74 years). None of the patients presented with any lymph node swelling, had a history of predisposing immunodeficiency or received immunodeficiency-inducing medications. Based on the international prognostic index score, three of five cases were categorized in the high-risk or high-intermediate-risk group. There were B symptoms (#2, 3, 4 and 6), neurologic symptoms (#1, 2, and 6), splenomegaly (#1 and 3) and respiratory symptoms (#4 and 6) noted. Of interest, the cases (#4 and 6) with respiratory symptoms were examined by chest CT, but showed no abnormality to explain the symptoms. Anemia and thrombocytopenia were noted in three cases (#1, 3, and 5) and one case (#3), respectively. All patients presented with elevated serum soluble interleukin-2 receptor. The follow-up periods ranged from less than one to 36 months. Two patients (#1 and 3) received no treatment and died within 0.5 months after their diagnoses. One case (#2) received only steroid pulse therapy and had a lethal clinical course 7 months after diagnosis. The remaining three cases were treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) and intrathecal injection therapy and achieved complete remission. They were alive at the time of the last follow-up. Figure 2 shows the histological features of all our cases. One case was diagnosed in an autopsy (#1) and the others from biopsies from the adrenal gland (#3 and 4), skin (#2), pelvic cavity (#5), and kidney (#6). One case (#1) was also accompanied by bone marrow involvement. All cases were characterized by a monomorphic population of large transformed B-cells with centroblastic appearance. Two IVLBCL cases (#1 and 2) showed the typical pattern of the selective growth of tumor cells within the lumina of vessels. The remaining four cases (#3 to 6) revealed a diffuse proliferation of large tumor cells; notably, three (case #3, 4, and 6) of them had a partially intravascular pattern. Table 3 summarizes the immunophenotypic features of our patients. In all cases, tumor cells were positive for CD20, BCL-2, MUM1, and PD-L1 (SP142), but were negative for c-Myc and EBER. CD10 and CD5 were detected in one case each (#1 and 6, respectively). The PD-L1 (SP142 clone) was expressed on >30% to >90% of the tumor cells in four cases (#1, 2, 3, and 5), and on 10% (case #4) and 20% (case #6) of the tumor cells in the other two cases. This neoplastic PD-L1 expression was also confirmed by the two other PD-L1 antibodies (E1J2J and 28-8) in five cases (#1 to 5); unfortunately, the other antibodies were not evaluated in case #6 because of the lack of available slides. The last case (#6) was positive for CD5 and diagnosed as de novo CD5þ DLBCL.
Histopathologic and immunophenotypic features
DISCUSSION
We report here six cases of extranodal DLBCL with expression of PD-L1 (SP142) on their tumor cells. Two cases had the clinicopathological features previously described as IVLBCL and there was one case of de novo CD5þ DLBCL. We demonstrated that neoplastic PD-L1þ extranodal large B-cell lymphoma exists beyond the currently recognized entities. It is characterized by exclusive extranodal involvement and frequent intravascular patterns of varying degrees. All patients were aged from 51 to 74 years at diagnosis. In all cases, the lymphoma showed a marked propensity to exclusively affect extranodal sites with no associated lymphadenopathy during their entire clinical courses. Clinical symptoms at presentation were largely attributable to the anatomical sites affected. All cases featured a monomorphic population of large transformed B-cells with a centroblastic appearance and a non-germinal center B-cell phenotype of CD20þ, BCL2þ, and MUM1þ. In addition, five of six cases were CD10þ, only case #1 was not.
An increasing number of reports have highlighted that PD-L1 is expressed on the tumor cells of certain solid carcinomas and lymphomas, mostly exemplified by classic Hodgkin lymphoma. 26 reported a frequent PD-L1 and PD-L2 translocation (40%), without copy number gains, in primary cutaneous DLBCL, leg type that induced overexpression of PD-L1. However, in our short series of CNS DLBCL, primary testicular DLBCL, and primary cutaneous DLBCL, leg type cases, we could not detect neoplastic PD-L1 expression, and this was confirmed using other PD-L1 antibodies, i.e. 28-8 and E1J2J clones. These data are not consistent with the recent findings of varying neoplastic PD-L1þ expression; although those results may be biased due to the varying sensitivities of the PD-L1 antibodies used. This issue should be addressed in future studies. Our neoplastic PD-L1þ series consisted of two IVLBCLs and four extranodal DLBCL cases, including one de novo CD5þ case. Three of the extranodal DLBCL cases might be IVLBCLs with diffuse "extra" vascular invasion or a gray zone lymphoma between IVLBCL and common extranodal DLBCL. By the time of diagnosis, IVLBCL is disseminated, warrants systemic chemotherapy, and carries a poor prognosis with 3-year overall survival rates of 60-81%. (Table 3 ). The neoplastic PD-L1 expression of IVLBCL cases might be associated with their tendency to affect immunological sanctuaries, such as the CNS, resulting in e.g., an elevated risk of CNS relapse 27 and neurolymphomatosis. 30 Indeed, Shimada et al. 3 reported that IVLBCL patients with CNS involvement at diagnosis tend to have a short interval from diagnosis to CNS recurrence. Similarly, patients with CNS DLBCL show a remarkably worse prognosis than those with systemic DLBCL, with about 25% of CNS DLBCL patients not responding to first-line treatment and over 50% of these non-responders relapsing during their clinical course. One (#6) of our cases was diagnosed as de novo CD5þ DLBCL, which was originally documented to have characteristics that were phenotypically and genotypically different than CD5-negative DLBCL and mantle cell lymphoma by Yamaguchi et al. 31, 32 This disease usually has a centroblastic morphology, with intravascular or intrasinusoidal infiltration in 19% of the cases. Among Japanese patients, this
CD5þ immunophenotype is often found in primary CNS DLBCL and IVLBCL cases. 33 In addition, CD5þ DLBCL was a risk factor for CNS recurrence in a study of 337 Japanese patients that found the 2-year risk for CNS relapse is high and that rituximab is not protective (11.6% for chemotherapy vs 12.7% for rituximab chemotherapy). 34 Although we cannot draw any definite conclusions because of the paucity of cases, the issue of neoplastic PD-L1 expression should be investigated in a larger series of de novo CD5þ DLBCL cases. The other three DLBCL, NOS type cases in our series were diagnosed by needle biopsy of the adrenal glands or pelvic cavity lesions. We could not find any specific pathologic findings in these three cases because of the limited utility of the available specimens. A previous report linked the finding of adrenal glands affected by DLBCL with a high risk of secondary CNS relapse. 35 These patients are now carefully followed.
It was reported that CNS DLBCL and primary cutaneous DLBCL, leg type have high incidences of somatic mutations of MYD88 (55 to 86% and 61 to 77%, respectively) 19, [36] [37] [38] [39] and CD79B (40 to 64% and 40%, respectively) 19, 39, 40 and immunohistochemical expression of neoplastic PD-L1 (38% and 19 to 100%, respectively). 18, 36, 41, 42 However, we found no PD-L1-positive cases in our CNS DLBCL (n ¼ 15) and primary cutaneous DLBCL, leg type (n ¼ 2) cases. It is unclear if this discrepancy may be biased because of differences in the PD-L1 antibodies used, etiologic factors, or other reasons. This issue should be clarified in future studies.
Our cases suggest that neoplastic PD-L1 expression on tumor cells may represent a stage beyond the currently segregated entities and subtypes of IVLBCL, de novo CD5þ DLBCL, and extranodal DLBCL of NOS type, with regards to pathogenesis. Thus, we suggested a new classification: immune evasion-related extranodal large B-cell lymphoma. This classification should be further examined in future studies. Moreover, the apparent importance of PD-L1 indicates it is a possible therapeutic target for immune checkpoint inhibitors. Future large series studies are warranted to investigate these possibilities.
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